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Abstract
The current optimization of 2,4-diarylaniline analogs (DAANs) on the central phenyl ring
provided a series of new active DAAN derivatives 9a–9e, indicating an accessible modification
approach that could improve anti-HIV potency against wild-type and resistant strains, aqueous
solubility, and metabolic stability. A new compound 9e not only exhibited extremely high potency
against wild-type virus (EC50 0.53 nM) and several resistant viral strains (EC50 0.36 – 3.9 nM),
but also showed desirable aqueous solubility and metabolic stability, which were comparable or
better than those of the anti-HIV-1 drug TMC278 (2). Thus, new compound 9e might be a
potential drug candidate for further development of novel next-generation NNRTIs.
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Since the first case of acquired immunodeficiency syndrome (AIDS) was reported by the U.
S. in 1981, the scientific progress in HIV/AIDS research has been extraordinary, especially
in the development of antiretroviral therapy (ART) that has proven to be life-saving to
millions of people. Recent scientific evidence has demonstrated that ART is also effective at
preventing infection1,2; thus it offers an unprecedented opportunity to control the AIDS
pandemic. Therefore, the discovery and development of novel highly potent anti-HIV drugs
is imperative.
Among current anti-HIV drugs, non-nucleoside reverse transcriptase inhibitors (NNRTIs)
are used in combination with other drugs as key components in the highly active
antiretroviral therapy (HAART)3,4. NNRTIs target an allosteric binding pocket on HIV-1
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reverse transcriptase (RT) in a noncompetitive manner to cause distortion of the three-
dimensional structure of the enzyme to inhibit RT catalytic function5. Currently, five
NNRTIs drugs have been approved by FDA and are marketed (Figure 1) with the
advantages of high potency and low toxicity. Despite the clinical high efficiency, the first-
generation NNRTIs drugs (nevirapine, delavirdine, efavirenz) are limited in clinical use due
to rapid emergence of drug-resistance. However, the second-generation NNRTI drugs
etravirine (TMC125, 1)6 and rilpivirine (TMC278, 2)7 greatly overcome this deficiency.
Both 1 and 2 possess potent antiviral activity with subnano- or low nano-molar EC50 values
against wild-type and a broad spectrum of mutated viral strains. There is also a higher
genetic barrier8,9 to delay the emergence of drug-resistance toward etravirine and
rilpivirine10. Although both drugs are poorly water soluble over a wide pH range, 2 has the
advantage of better bioavailability when compared to 1, resulting in a once-daily oral
dosing. The success of etravirine and rilpivirine greatly encouraged more research to explore
additional novel next-generation NNRTI agents with new scaffolds, high potencies,
improved resistant profiles, and better pharmacokinetic profiles than 1 and 2 for more
efficacious therapy and potential AIDS prevention.
In prior studies toward the design and synthesis of novel next-generation NNRTIs, we
discovered a series of new diarylanilines (DAANs, Figure 2) with nano- to subnano-molar
anti-HIV potencies against wild-type and multi-RT-resistant viral strains11,12, as
exemplified by compound 3 with higher potency against wild-type (EC50 0.38 nM) and RT
multi-resistant viral strains (EC50 0.87 nM) than 1 in the same assays. Previous SAR results
also defined the key pharmacophores of DAANs as NNRTIs: (1) a para-cyanoaniline moiety
(A-ring), (2) a crucial amino group on the central phenyl ring (B-ring) ortho to the A-ring
position, (3) a trisubstituted phenoxy ring (C-ring) with a para-linear hydrophobic
substituent, and (4) similar molecular flexibility to 1 and 2. Their high potency and
straightforward synthesis prompted us to develop DAANs as new anti-AIDS drug
candidates. For orally anti-HIV drug candidates, aqueous solubility is one of the most
critical physicochemical properties to be considered in the process of lead optimization,
because low aqueous solubility would limit molecular absorption and bioavailability in vivo.
On the other hand, most small organic molecules generally have poor water solubility.
Therefore, our current optimization of DAANs must generate active DAANs with desirable
molecular aqueous solubility. Our early results indicated that the nitro group (R1) on the
central phenyl ring (B-ring) of DAANs was associated with antiviral potency by creating a
small electrostatic interaction with the positively charged amino acid K172 on the NNRTI
binding site.11 Thus, we proposed that other polar or ionizable groups, similar to the nitro
group, on the B-ring might provide comparable or additional interaction point(s) with the
NNRTI binding site via a “salt bridge” and/or H-bonds to enhance antiviral potency.
Furthermore, the presence of R1 substituent(s) to serve as a H-bond acceptor or donor is
expected to be favorable for improving aqueous solubility. Therefore, a series of new
DAAN derivatives with different R1 groups on the central phenyl ring are reported herein,
including chemical synthesis, antiviral activity, aqueous solubility, and metabolic stability in
vitro.
As shown in Scheme 1, the nitration of 2,4-dichlorobenzoic acid, a commercially available
and inexpensive reagent, was performed with concentrated HNO3 in H2SO4 at low
temperature (0–5 °C) to produce 2,4-dichloro-5-nitrobenzoic acid (4) with a 91% yield.
Compound 4 was esterified with MeOH in the presence of H2SO4 to afford methyl 2,4-
dichloro-5-nitrobenzoate (5). Coupling of 5 and 4-aminobenzo-nitrile was performed in
DMF in the presence of excess cesium carbonate at 100 °C for about 10 h to provide methyl
2-chloro-4-(4-cyanophenyl amino)-5-nitrobenzoate (6), which was characterized by an NH
signal at δ 9.76 ppm in the 1H NMR spectrum, ascribable to the chelated nitro group and
consistent with previous results that the chlorine ortho to the nitro group has higher
Sun et al. Page 2













reactivity for nucleophilic substitution with an aromatic amine. Next, intermediate 6 was
reacted with 4-hydroxy-3,5-dimethylbenzaldehyde under microwave irradiation in DMF in
the presence of potassium carbonate with stirring at 190 °C for about 15 min to afford 7 with
a three-phenyl ring skeleton in a 67% yield. Subsequently, the aldehyde group in 7 was
converted into a cyanovinyl moiety by condensation with diethyl cyanomethyl phosphonate
in the presence of potassium tert-butoxide to afford compound 8a. Then, the ester group in
8a was hydrolyzed under basic conditions to afford the corresponding benzoic acid
compound 8b. The carboxylic acid group was then converted into an amide or N-methyl
amide by treatment with SOCl2, followed with ammonia or methylamine to afford
corresponding compounds 8c and 8d respectively. In addition, the ester group in 8a was
reduced with LiBH4 to provide compound 8e with a hydroxymethyl substituent. Finally, the
nitro group on the central ring in compounds 8a–8e was reduced by using sodium
hydrosulfite dehydrate to produce corresponding target compounds 9a–9e, a series of 5-
substituted 2-(4-cyanophenylamino)-4-(4-cyanovinyl-2,6-dimethylphenoxy)anilines.13
New compounds 9a–9e were first tested against wild-type HIV-1 NL4-3 infection of TZM-
bl cells in parallel with TMC278 and 3. The data are summarized in Table 1. Compounds 9c
(R1 = CONH2) and 9e (R1 = CH2OH) exhibited extremely high potency with EC50 values of
0.87 nM and 0.53 nM, respectively, and both showed high selective indexes (SIs) of
>27,126, comparable to those of new drug 2 (TMC278) and 3 in the same assay.
Compounds 9a (R1 = COOCH3) and 9d (R1 = CONHCH3) were also potent with EC50
values of 2.7 nM and 5.7 nM, respectively, and SI values of > 8464 and >1606, respectively.
On the other hand, 9b with a carboxylic acid group (R1 = COOH) was significantly less
potent (EC50 230 nM). Thus, the current results, even with the limited data set, demonstrated
that the R1 substituent on the central phenyl ring was modifiable and could greatly affect
antiviral potency. The aqueous solubility of new compounds 9a–9e at pH 7.4 and pH 2.0
were measured by a HPLC/UV method in parallel with 2 and 3, and the data are also shown
in Table 1. Compared to 2 and 3, all new 9 series compounds had improved aqueous
solubility at pH 7.4 and were generally more soluble at pH 2.0, likely due to the presence of
a free amino group. The most active new compound 9e (R1 = CH2OH) showed better
aqueous solubility (3.23 μg/mL at pH 7.4 and 21.0 μg/mL at pH 2.0) than the remaining
four compounds in the series. Subsequently, the most active compounds 9c and 9e were
selected for testing against NNRTI resistant HIV-1 mutants RT-multi-drug-resistant
(RTMDR), K101E, and E138K. As shown in Table 2, new compounds 9c and 9e exhibited
improved antiviral activity compared to 3 against the drug resistant viral strains, and a little
better or comparable to those of 2. Compounds 9c and 9e were further evaluated in rat and
human liver microsome (RLM and HLM, respectively) assays in vitro,14,15 respectively, to
predict their metabolic stability in vivo. The two data sets in Table 2 indicated a similar
metabolic stability pattern. Compounds 9c and 9e had moderate stability with half-lives of
35 min and 30 min in HLM and 122 min and 84 min in RLM assays, respectively.
Compound 9c had a longer maintaining time (was more stable) than 9e in both assays, and
both compounds showed comparable metabolic stability to that of 2 (t1/2 34 min) in the
HLM assay.
In conclusion, our optimization focused on the central phenyl ring of DAANs provided a
series of new active compounds 9a–9e and also verified our previous hypothesis that the R1
substitution could optimize the antiviral potency and drug-like properties. This study
resulted in the discovery of a new compound 9e that not only exhibited extremely high
potency against wild-type virus (EC50 0.53 nM) and several resistant viral strains (EC50 0.36
– 3.9 nM), but also showed desirable aqueous solubility and metabolic stability, which were
better than those of drug 2. Thus, compound 9e could serve as a potential drug candidate for
further development.
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Reagent and conditions: (a) HNO3/H2SO4, 0–5 °C to r.t., 2 h; (b) H2SO4/MeOH, reflux, 2 h;
(c) Cs2CO3/DMF, 100 °C, 10 h; (d) K2CO3/DMF, 190 °C, microwave, 10–15 min; (e)
(EtO)2P(O)CH2CN, t-BuOK/THF, 0 °C to r.t., 3 h; (f) THF/MeOH, aq NaOH, 0.5 h; (g) (i)
CH2Cl2/SOCl2, reflux, 3 h; (ii) ammonia in THF, 0 °C, 0.5 h; (h) (i) SOCl2/CH2Cl2, reflux,
3 h; (ii) methylamine in THF, 0 °C, 0.5 h; (j) LiBH4, THF/MeOH, 1 h; (k) Na2S2O4,
ammonia, THF/H2O (1:1, v/v), r.t., 2 h.
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